Cutaneous manifestations of vemurafenib therapy for metastatic melanoma

Joshua L. Owen, Isha E. Lopez, Seemal R. Desai

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Vemurafenib, a BRAF inhibitor, is FDA-approved for the treatment of metastatic melanoma in patients who harbor the BRAF V600E mutation. By inhibiting BRAF, vemurafenib prevents the mitogen-activated protein kinase (MAPK) pathway from driving melanoma growth. Here we present a patient with paradoxical activation of the MAPK pathway by vemurafenib, ultimately resulting in deleterious cutaneous manifestations. An emphasis on close follow-up is warranted for new or changing lesions for patients on this medication and other BRAF inhibitors.

Original languageEnglish (US)
Pages (from-to)509-510
Number of pages2
JournalJournal of drugs in dermatology : JDD
Issue number5
StatePublished - May 1 2015

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Cutaneous manifestations of vemurafenib therapy for metastatic melanoma'. Together they form a unique fingerprint.

Cite this